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Accepted 9 March 2012AbstractObjective: To evaluate the efficacy and toxicity of topical imiquimod for the treatment of persistent human papillomavirus (HPV) infection in
patients with or without cervical/vaginal intraepithelial neoplasia (CIN/VAIN).
Methods: Patients with persistent HPV infection (1 year) after a history of treatment for cervical or vaginal neoplasm but normal histology and
cytology, abnormal Papanicolaou (Pap) smears without abnormal histology, and untreated histology-documented CIN/VAIN Grade 1/2/3 with
HPV-positive testing were recruited. Patients were instructed to apply 250 mg of 5% imiquimod cream intravaginally on consecutive days or at
least twice weekly on an outpatient basis for a minimum of 12 doses. A group of age- and previous diagnosis-matched, imiquimod-untreated
historical controls (n ¼ 20) were selected. The main outcome measures included HPV DNA detection, cytology, and colposcopy/histology at 6
months after treatment.
Results: A total of 72 patients were eligible for analysis. At a median follow-up of 33.6 months, 37 patients (51.4%) had cytological/histological
regression and tested HPV-negative. Six patients (8.3%) had progressive cytology/histology with persistent HPV infections. Of the 72 treated
patients, 26 patients who had a normal Pap test but were persistently HPV-positive for at least 1 year had a complete regression rate of 65.4%,
which was significantly different from the rate (30%) observed in the untreated historical control ( p ¼ 0.036). Six patients with histologically
proven CIN2/3 or VAIN2/3 had a complete regression rate of 66.6% (4/6).
Conclusions: The tolerability of intravaginal self-administered imiquimod is confirmed. Its efficacy in the treatment of women with persistent
HPV infection and normal cytology warrants further randomized, controlled trials to determine appropriate dosages and scheduling.
Copyright  2012, Taiwan Association of Obstetrics & Gynecology. Published by Elsevier Taiwan LLC. All rights reserved.
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There is substantial epidemiological and molecular
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http://dx.doi.org/10.1016/j.tjog.2012.09.006intraepithelial neoplasia (CIN) [1]. The incorporation of HPV
testing with cervical cytology in primary cervical cancer
screening has been widely used [2]. However, identifying
women with normal cytology and histology who are infected
with high-risk HPV may result in substantial anxiety for these
women [3]. HPV-related emotional distress has been noted.
Therefore, a strategy to effectively manage persistent HPV
infection or inflammation would have far-reaching global
health and economic impact. HPV testing as triage for
borderline or mild dyskaryosis and follow-up after conizationcs & Gynecology. Published by Elsevier Taiwan LLC. All rights reserved.
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secondary neoplasia in the genital tract or relapse may occur
more than 5 or 10 years later [8,9], and follow-up for women
with persistent high-risk HPV infection can only be performed
periodically.
As compared to CIN, studies on the natural history of
vaginal intraepithelial neoplasia (VAIN) are relatively limited
[10]. In addition, the relationship between persistent HPV
infection and progression in vaginal neoplasia is still unclear
[11e13]. In the management of CIN/VAIN, CIN1 can be
observed within 2 years if it is nonprogressive while CIN2
lesions are excised. A conservative management policy is
generally applied to special populations, including adolescents
and pregnant women [14]. VAIN may be difficult to manage,
especially in the presence of multifocal lesions when the
vaginal vault is involved after hysterectomy [15]. Surgical
excision is the mainstay of treatment for high-grade VAIN, but
various other modalities, including carbon dioxide laser
therapy, 5-fluorouracil cream application, and cryotherapy
have been proposed [15]. In a previous study of 132 women,
eight cases progressed from high-grade VAIN to invasive
cancer, whereas seven of the eight VAIN1 patients regressed
during an observational approach after biopsy [16].
Treatment of CIN or VAIN after the failure of standard
therapy is challenging. Imiquimod (5% cream) has been
shown to be safe and effective in the treatment of genital warts
caused by low-risk HPV infections [17,18]. Topical imiquimod
has also been used for oral leukoplakia [19], basal cell carci-
noma [20], vulvar intraepithelial neoplasia (VIN) [21,22], and
VAIN [23e26]. The mechanism for the eradication of genital
verrucous lesions with imiquimod may involve the induction
of both innate and cellular immunity [18]. Antiviral activity
may be stimulated through the induction of cytokines, such as
interferon-a (IFN-a), tumor necrosis factor-a (TNF-a), and
interleukins (ILs) [18]. It is known that imiquimod activates
immune cells through the toll-like receptor 7 (TLR7),
commonly involved in pathogen recognition, on the cell
surface. Cells activated by imiquimod via TLR7 secrete
cytokines such as IFN-a, IL-6, and TNF-a. There is evidence
that imiquimod, when applied to skin, cervix, or vagina, can
lead to the activation of naı¨ve dendritic cells, which subse-
quently migrate to local lymph nodes to activate the adaptive
immune system. Other cell types activated by imiquimod
include NK cells, macrophages, and B-lymphocytes [18,27].
In this retrospective study, we sought to determine the
efficacy and toxicity of self-administered topical 5% imiqui-
mod cream for the treatment of persistent HPV infections
either with or without CIN/VAIN involvement.
Patients and methods
This retrospective study was approved by the Institutional
Review Board (IRB) of the Chang Gung Memorial Hospital.
Patients with persistent HPV infection (1 year) after a history
of treatment for cervical or vaginal neoplasms (Group 1),
abnormal Papanicolaou (Pap) smears without abnormal
histology (Group 2), and untreated histology-documentedCIN/VAIN Grade 1/2/3 (Group 3) with HPV-positive testing
were recruited. Abnormal Pap smears were defined as those
containing atypical squamous cells of undetermined signifi-
cance (ASCUS) or worse. The participants were informed
about the treatment and possible complications and accepted
the off-label use of imiquimod (Aldara; 3M Health Care
Limited, Leicester, UK). Patients were instructed to apply
250 mg of 5% imiquimod cream intravaginally, using their
fingers to reach the exocervix or vaginal vault, every other day
or at least twice weekly on an outpatient basis for a minimum
of 12 doses.
HPV DNA testing primarily used a Hybrid Capture II
method (Digene Corporation, Gaithersburg, MD, USA),
which detects 13 different carcinogenic HPV types. The
procedures for collecting and transporting the specimens
were conducted according to the manufacturer’s instructions
[6]. A positive cutoff value was set at 1 pg HPV DNA per mL
in the specimen. HPV detection using SPF1/GP6þ poly-
merase chain reaction plus genotyping with Easychip HPV
Blot (King Car, I-Lan, Taiwan) was performed in selected
patients [28,29].
The clinical outcomes were classified as progressive, stable
disease, or complete regression. Colposcopy and cytology
were usually performed at each visit when histology/cytology
abnormalities remained or HPV testing was persistently
positive. Complete regression criteria were satisfied only if
cytology/colposcopy results were normal and HPV tests were
negative. Progression was defined by cytologic or histological
progression of 1 grade and persistently positive HPV. All
others were considered to be a stable disease outcome (such as
cytologic improvement that was not accompanied by reversion
to a normal Pap smear or persistent positive HPV testing or
Pap of ASCUS with negative HPV test). HPV follow-up status
was classified as either positive or negative. The duration of
response was required to last for at least 6 months to be
declared a success.
A group of age- and previous diagnosis-matched, untreated
historical controls of Group 1 were selected for comparison
from our ongoing follow-up cohorts. These controls had normal
Pap and colposcopy/histology results but were persistently
HPV-positive for at least 1 year were eligible if they had
a follow-up HPV test at least 6 months following the second
HPV-positive test and: (1) a previous history of CIN2/3 with
hysterectomy (grant CMRPG 371641); (2) a previous history of
CIN2/3 without hysterectomy (grant CMRPG380731); (3)
a baseline normal cytology but positive HPV tests (grant
NSC97-2314-B-182-013-MY3); or (4) a history of abnormal
Pap results or cervical neoplasia that did not fit into the above
prospective studies.
All calculations were performed using the SPSS 15.0
statistical package (SPSS, Inc., Chicago, IL, USA). Associa-
tions between categorical variables were assessed using the
Chi-square statistical analysis. Comparisons between the
historical control group and the imiquimod treatment group
were performed using the Kaplan-Meier method (log-rank
test). A two-sided -p-value < 0.05 was considered to be
statistically significant.
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Between February 2003 and July 2007, 72 patients were
eligible for analysis (Table 1). Based on the histology and
cytology results upon entry into treatment, the study patients
were grouped as follows: Group 1 (n ¼ 26), patients with
persistent HPV infection (1 year) but normal histology and
cytology; Group 2 (n ¼ 20), patients with abnormal Pap tests
but negative histology (9 ASCUS, 2 atypical squamous cells,
cannot rule out a high grade lesion, 8 low-grade squamous
intraepithelial lesions, and 1 high-grade squamous intra-
epithelial lesion); and Group 3 (n ¼ 26), patients with histo-
logical diagnoses of CIN/VAIN Grade 1/2/3 (20 CIN1/VAIN1,
3 CIN2/ VAIN2, 2 VAIN3, and 1 CIN3).
The median age of the study population was 54 years
(range 26e88 years). Ten patients had previously been diag-
nosed with cervical cancer (5 radical hysterectomies and 5
radiation/concurrent chemoradiation treatments), 29 patients
had prior CIN/VAIN 2/3 diagnoses (10 hysterectomies, 18
conizations, and 1 biopsy), 29 patients had prior CIN1/VAIN1
diagnoses (9 conizations, 17 biopsies, 1 partial vaginectomy,
and 2 laser therapies), two patients had ASCUS, one patient
had endometrial cancer (abnormal vaginal Pap test at post-
therapy surveillance), and one patient underwent a hysterec-
tomy for adenomyosis (symptomatic with an abnormal vaginal
Pap smear). The clinical profile of the historical control group
is also summarized in Table 1.
The first HPV test for the eligible patients occurred 3e6
months from the initiation of imiquimod treatment. Overall,
38 women (52.8%) had HPV regression, and 37 women
(51.4%) were both HPV-negative and had normal cytological
and histological findings at a median follow-up of 33.6
months. Six patients (8.3%) had lesions that progressed and
persistent HPV infections (Table 2). Additionally, 20 of 34
patients (58.8%) with persistent HPV infection also had
complete regression in their cytology/histology results.
Complete regression was achieved in 17 of 26 patients
(65.4%) in Group 1. Of the 20 women in Group 2, nine (45%)
reverted to HPV-negative status with normal cytologic findings
following treatment with imiquimod. In Group 3, 11 women
(42.3%) reverted to HPV-negative status.
The side effects of imiquimod treatment were acceptable
(Table 3); no participant discontinued medication due to
adverse effects in the present study. The most frequent side
effect was increased vaginal discharge. Other side effects ofTable 1
Characteristics of imiquimod-treated groups and the historical control group.
Group 1 (n ¼ 26) Group 2 (n ¼ 20) Group 3
Median age, y (range) 54 (32e80) 48.5 (35e75) 54 (26e
Past history
ASCUS 0 2 0
CIN1 10 6 13
CIN2/3 12 7 10
Cervical cancer 4 3 3
Endometrial cancer 0 1 0
Adenomyosis 0 1 0
ASCUS ¼ atypical squamous cells of undetermined significance; CIN ¼ cervicalimiquimod included vulvar pain, pruritus, myalgias, and flu-
like symptoms. The investigators also noted skin reactions,
including erythema and erosions.
To examine the efficacy of imiquimod treatment, the
complete regression rate of Group 1 imiquimod-treated
patients was compared with that of individuals in the histor-
ical control group. Of the 20 matched controls who had
a follow-up HPV test at least 6 months following the second
HPV-positive test, six (30.0%) had HPV clearance without
developing new Pap or histological abnormalities. There was
a significant difference in the clearance rates between the
imiquimod-treated patients and the historical control individ-
uals in Group 1 ( p ¼ 0.036, log-rank test). In Group 1, the
mean time of HPV clearance was 13.2 months (complete
regression in 16 of 17 patients occurred within 24 months),
which was much faster than that observed in the historical
control group (36.2 months, Fig. 1).
Discussion
The clinical utility of the integration of HPV detection in
cytology in the follow-up of women treated for CIN has been
confirmed [29]. However, persistent HPV infection is quite
prevalent in women who suffered from prior CIN lesions [6].
We retrospectively analyzed 72 patients who underwent self-
administered imiquimod treatment. An HPV regression and
normal cytology/histology rate of 51.4% over a median
follow-up time of 33.6 months was found within the entire
patient cohort. Of the 26 patients who had a normal Pap test
but were persistently HPV positive for at least 1 year
(Group 1), there was a regression rate of 65.4%, which was
significantly different from the rate observed for the untreated
historical control group (30%, n ¼ 20; p ¼ 0.036). Unfortu-
nately, women with a concomitant abnormal cytology
(Group 2) or CIN or VAIN 1/2/3 diagnosis (Group 3) appeared
to be less likely to regress, exhibiting regression rates of 40%
and 46.1%, respectively.
A recent review of the VAIN response to imiquimod
treatment [30,31] demonstrated that the complete response
rates ranged from 50% [25] to 86% [23, 26], and the partial
response rates ranged from 14% [26] to 25% [25]. Buck et al
[23] noted that 86% of the 42 women available for follow-up
(mostly low-grade VAIN) showed clearance upon colposcopic
evaluation after self-administering imiquimod treatment once
weekly. Diaz-Arrastia et al [25] also treated patients with self-(n ¼ 26) Entire cohort (n ¼ 72) Historical control group (n ¼ 20)









Cytological and human papillomavirus (HPV) changes following imiquimod application based on pretreatment cytology, histology, and group (n ¼ 72).
Pretreatment cytology and histology (number of patients)
Posttreatment outcomes, n (%)
Stable disease Complete regression Progression
HPVþ HPVe HPVe HPVþ HPVe
Pre-treatment cytology
Normal (32) 9 (28.1) 1 (3.1) 20 (62.5) 2 (6.3) 0
LSIL (19) 9 (47.4) 0 9 (47.4) 1 (5.3) 0
HSIL (2) 1 (50) 0 0 1 (50) 0
ASCUS (16) 7 (43.7) 0 7 (43.7) 2 (12.5) 0
ASC-H (3) 2 (66.7) 0 1 (33.3) 0 0
Pretreatment histology
Group 1 Cytology nl, colposcopy nl (24) 6 (25) 1 (4.2) 15 (62.5) 2 (8.3)b 0
Cytology nl, colposcopy abnl (2)a 0 0 2 (100) 0 0
Group 2 Cytology abnl, bx nl (7) 4 (57.1) 0 2 (28.6) 1 (14.3) 0
Cytology abnl, colposcopy nl (13) 5 (38.5) 0 7 (53.8) 1 (7.7) 0
Group 3 CIN1/VAIN1 (20) 12 (60) 0 7 (35) 1 (5) 0
CIN2,3/ VAIN2,3 (6) 1 0 4 (66.6) 1 (16.7) 0
Abnl ¼ abnormal; ASCUS ¼ atypical squamous cells of undetermined significance; ASC-H ¼ atypical squamous cells e cannot exclude high-grade lesions;
bx ¼ biopsy, CIN ¼ cervical intraepithelial neoplasia; HSIL ¼ high-grade squamous intraepithelial lesion; LSIL ¼ low-grade squamous intraepithelial lesion;
nl ¼ normal; VAIN ¼ vaginal intraepithelial neoplasia.
a Biopsy results were negative; b One patient progressed to CIN2 at 16 months and another to CIN1 in histology at 15 months after imiquimod treatment. The
patients who had cytologic/histologic regression and tested HPV-negative are denoted in bold text.
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high-grade CIN, and two patients had high-grade VAIN. Four
patients exhibited a complete response to treatment, two
patients exhibited a partial response to treatment, and one
patient progressed despite treatment. Of the four complete
responders, two patients remained disease-free (mean follow-
up: 33 months). Haidopoulos et al [26] reported that six of
seven patients with VAIN2/3 had vaginal dysplasia that
regressed by at least two grades in response to physician-
administered imiquimod therapy. In contrast, only 12
(46.1%) had HPV reversion to negative status in Group 3 of
our study cohort. However, none of these previous studies
required the complete clearance of HPV infection at the
primary end point, which results in different success rates
between our study and other reports. Additionally, our study is
the largest thus far that has examined the use of intravaginal
imiquimod therapy.
In terms of anatomic accessibility by topical application,
imiquimod is better suited for VIN patients. For treating
lesions in the vagina or cervix, the self-application of topical
imiquimod has disadvantages. However, we postulate thatTable 3
Side effects of imiquimod treatment.
Side effects Number of patients





Increased vaginal discharge 7
Indicated by the physician
Mild erosion 2
Mild erythema 1
Fever 3HPV infection in the female genital tract could be multifocal,
and an enhanced immune response could be widespread. Thus,
an accurate application to the lesion site may not be critical.
Moreover, this application method is more convenient for the
patient if it achieves the desired results.
There were limitations to the current study. This was
a retrospective study with a small sample size. Additionally,
most of the cases in the study cohort were analyzed using the
Hybrid Capture II HPV testing. HPV genotyping was per-
formed in a small number of the participants, and we classified
the patient’s HPV status as positive or negative regardless of
the type-specific persistence or whether it was a newly
acquired infection.Fig. 1. Cumulative clearance curves for subjects in Group 1 and the historical
control group ( p ¼ 0.036).
537C.-T. Lin et al. / Taiwanese Journal of Obstetrics & Gynecology 51 (2012) 533e538The clinical value of treating persistent HPV infection with
normal cytology remains controversial. With the wide appli-
cation of HPV primary screening, a large number of women
may experience substantial anxiety knowing that they are
carrying a persistent, high-risk HPV infection in their lower
genital tracts. Intravaginal imiquimod treatment may be
a viable option for these women if it is proven effective by
well-designed placebo-controlled, randomized trials. If
selecting Group 2 or 3 patients, a sample size of 170 patients
in each arm would be required to achieve 80% power for the
detection of a 15% improvement in the treatment arm versus
a spontaneous regression rate of approximately 30% in the
placebo group using a two-sided c2 test. A much smaller
sample size would be necessary for Group 1 patients.
In conclusion, 51.4% of patients had cytologic/histologic
regression and tested HPV-negative after treatment with
12  250 mg doses of intravaginal, self-administered imi-
quimod. The rates of HPV clearance (69.2%) in women who
had a normal Pap test but were persistently HPV-positive for at
least 1 year were significantly different from those of the
untreated historical control group (30%). The tolerability of
intravaginal, self-administered imiquimod has been confirmed.
Its efficacy in the treatment of women with persistent HPV
infection and normal cytology warrants further randomized,
controlled trials to determine appropriate dosages and
scheduling.
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